Opdivo’s Sales Growth and Its Role as a Core Product in the Portfolio
First written in FY2016. 6 of 35 entries say "Advanced", first in FY2017-Q1. Latest entry: FY2026.
0 other companies' latest entry also says "Other".
- FY2026Decline in Opdivo product sales and increase in royalty incomeAnnual report
「For the full fiscal year, Opdivo product sales fell by ¥6.0 billion, or 5.0%, from the previous fiscal year to ¥114.3 billion due mainly to the intensifying competitive environment. Royalty and other revenue rose by ¥17.1 billion, or 10.9%, to ¥173.2 billion as royalty income from Bristol Myers Squibb and other companies increased.」
For the full fiscal year, Opdivo product sales declined due mainly to the intensifying competitive environment, while royalty and other revenue increased. - FY2026-H1Interim-period decline in product sales and increase in royalty incomeAnnual report
「Product sales of the antineoplastic drug Opdivo Intravenous Infusion fell by ¥4.1 billion, or 6.5%, year on year to ¥58.5 billion due mainly to the intensifying competitive environment. Royalty and other revenue rose by ¥5.1 billion, or 6.7%, to ¥82.2 billion as royalty income from Bristol Myers Squibb and other companies increased.」
In the interim period, Opdivo product sales declined while royalty and other revenue increased, and the shift in the revenue mix continued. - FY2025Both product sales and royalty income declined for the full fiscal yearAnnual report
「Product sales of the antineoplastic drug Opdivo Intravenous Infusion fell by ¥25.2 billion, or 17.3%, from the previous fiscal year to ¥120.3 billion due mainly to the drug price reduction. Royalty and other revenue fell by ¥29.6 billion, or 15.9%, to ¥156.1 billion, reflecting the decline from the previous fiscal year's ¥17.0 billion one-time payment received in connection with the settlement of patent litigation with AstraZeneca and a decrease due to lower royalty rates from Merck and other companies.」
For the fiscal year ended March 2025, both Opdivo product sales and royalty and other revenue declined, while the comparison with the previous year's one-time settlement payment and lower royalty rates also affected the revenue mix. - FY2025-H1Both product sales and royalty income declined in the interim periodAnnual report
「Product sales of the antineoplastic drug Opdivo Intravenous Infusion fell by ¥12.4 billion, or 16.5%, year on year to ¥62.6 billion due to the impact of the drug price reduction. Royalty and other revenue fell by ¥21.8 billion, or 22.0%, to ¥77.0 billion, reflecting the decline from the previous year's ¥17.0 billion one-time payment received in connection with the settlement of patent litigation with AstraZeneca and a decrease in royalty income from Merck and other companies due to lower royalty rates.」
Opdivo product sales declined due to the drug price reduction, while royalty and other revenue also declined because of the comparison with the previous year's one-time settlement payment and lower royalty rates. - FY2024AdvancedAnnual report
「While the competitive environment intensified, product sales rose by ¥3.1 billion, or 2.2%, from the previous fiscal year to ¥145.5 billion, as use expanded in gastric cancer, esophageal cancer, urothelial cancer and other indications.」
Opdivo product sales were ¥145.5 billion, up 2.2% year on year against a backdrop of expanded use across multiple cancer types. - FY2024-Q3AdvancedAnnual report
「While the competitive environment intensified, product sales rose by ¥5.8 billion, or 5.3%, year on year to ¥114.9 billion, as use expanded in gastric cancer, esophageal cancer, urothelial cancer and other indications.」
For the nine months ended the third quarter, Opdivo product sales were ¥114.9 billion, up 5.3% year on year. The disclosure describes expanded use in gastric cancer, esophageal cancer, urothelial cancer and other indications. - FY2024-Q1Both Opdivo product sales and royalty income increased in the first quarterAnnual report
「While the competitive environment intensified, product sales rose by ¥3.7 billion, or 10.9%, year on year to ¥37.8 billion, as use expanded in gastric cancer, esophageal cancer, urothelial cancer and other indications. Royalty and other revenue rose by ¥4.9 billion, or 14.2%, year on year to ¥39.5 billion.」
In the first quarter, Opdivo product sales were ¥37.8 billion and royalty and other revenue was ¥39.5 billion, with both increasing year on year. - FY2023Both product sales and royalty income increased for the full fiscal yearAnnual report
「While competition with rival products intensified, product sales rose by ¥29.9 billion, or 26.6%, from the previous fiscal year to ¥142.3 billion, as use expanded in gastric cancer, esophageal cancer and other indications. Royalty and other revenue rose by ¥36.7 billion, or 31.8%, to ¥152.1 billion.」
For the fiscal year ended March 2023, both Opdivo product sales and royalty and other revenue increased, and the revenue stream remained a core contributor. - FY2023-Q3Both product sales and royalty income increased in the third quarterAnnual report
「While competition with rival products intensified, product sales rose by ¥24.1 billion, or 28.3%, year on year to ¥109.1 billion, mainly because use expanded in gastric cancer, esophageal cancer and other indications. Royalty and other revenue rose by ¥27.9 billion, or 32.7%, year on year to ¥113.5 billion.」
For the nine months ended the third quarter, Opdivo product sales were ¥109.1 billion and royalty and other revenue was ¥113.5 billion, with both increasing year on year. - FY2023-Q2Both product sales and royalty income increased in the first halfAnnual report
「While competition with rival products intensified, product sales rose by ¥13.8 billion, or 24.6%, year on year to ¥69.9 billion, mainly because use expanded in gastric cancer, esophageal cancer and other indications. Royalty and other revenue rose by ¥16.9 billion, or 30.8%, year on year to ¥71.8 billion.」
For the six months ended the second quarter, Opdivo product sales were ¥69.9 billion and royalty and other revenue was ¥71.8 billion, with both increasing year on year. - FY2023-Q1Both Opdivo product sales and royalty income increased in the first quarterAnnual report
「While competition with rival products intensified, product sales rose by ¥5.1 billion, or 17.4%, year on year to ¥34.1 billion, mainly because use expanded in first-line treatment of gastric cancer, adjuvant treatment of esophageal cancer and first-line treatment of non-small cell lung cancer. Royalty and other revenue rose by ¥7.7 billion, or 28.8%, year on year to ¥34.6 billion.」
In the first quarter of the fiscal year ending March 2023, Opdivo product sales were ¥34.1 billion and royalty and other revenue was ¥34.6 billion, with both increasing year on year. - FY2022Both Opdivo product sales and royalty income increased for the full fiscal yearAnnual report
「While competition with rival products intensified, product sales rose by ¥13.6 billion, or 13.8%, from the previous fiscal year to ¥112.4 billion, mainly because use expanded in first-line treatment of non-small cell lung cancer, esophageal cancer and first-line treatment of gastric cancer. Royalty and other revenue rose by ¥20.7 billion, or 21.8%, to ¥115.4 billion.」
For the fiscal year ended March 2022, Opdivo product sales were ¥112.4 billion and royalty and other revenue was ¥115.4 billion, with both revenue streams increasing from the previous year. - FY2022-Q3Both product sales and royalty income increased in the third quarterAnnual report
「While competition with rival products intensified, product sales rose by ¥8.7 billion, or 11.4%, year on year to ¥85.1 billion, mainly because use expanded in first-line treatment of non-small cell lung cancer and second-line treatment of esophageal cancer. Royalty and other revenue rose by ¥16.0 billion, or 23.0%, year on year to ¥85.5 billion.」
For the nine months ended the third quarter, Opdivo product sales were ¥85.1 billion and royalty and other revenue was ¥85.5 billion, with both increasing year on year. - FY2022-Q2Both product sales and royalty income increased in the first halfAnnual report
「While competition with rival products intensified, product sales rose by ¥7.0 billion, or 14.3%, year on year to ¥56.1 billion, mainly because use expanded in first-line treatment of non-small cell lung cancer and second-line treatment of esophageal cancer. Royalty and other revenue rose by ¥10.9 billion, or 24.8%, year on year to ¥54.9 billion.」
For the six months ended the second quarter of the fiscal year ending March 2022, both Opdivo product sales and royalty and other revenue increased year on year. - FY2022-Q1Both product sales and royalty income increased in the first quarterAnnual report
「While competition with rival products intensified, product sales rose by ¥4.6 billion, or 18.7%, year on year to ¥29.0 billion, mainly because use expanded in first-line treatment of lung cancer and second-line treatment of esophageal cancer. Royalty and other revenue rose by ¥5.5 billion, or 25.7%, year on year to ¥26.8 billion.」
In the first quarter, product sales increased against a backdrop of expanding Opdivo use, while royalty and other revenue also increased year on year. - FY2021-Q3Both product sales and royalty income increased in the third quarterAnnual report
「While competition with rival products intensified, product sales rose by ¥8.3 billion, or 12.3%, year on year to ¥76.3 billion, mainly because use in esophageal cancer expanded. Royalty and other revenue rose by ¥5.3 billion, or 8.2%, year on year to ¥69.5 billion.」
For the nine months ended the third quarter, Opdivo product sales were ¥76.3 billion and royalty and other revenue was ¥69.5 billion, with both increasing year on year. - FY2021-Q2Both Opdivo product sales and royalty income increased in the first halfAnnual report
「While competition with rival products intensified, product sales rose by ¥2.3 billion, or 4.8%, year on year to ¥49.1 billion, as use in renal cell carcinoma and gastric cancer remained steady and use in esophageal cancer expanded. Royalty and other revenue rose by ¥1.7 billion, or 4.1%, year on year to ¥44.0 billion.」
For the six months ended the second quarter of the fiscal year ending March 2021, Opdivo product sales were ¥49.1 billion and royalty and other revenue was ¥44.0 billion, with both increasing year on year. - FY2021-Q1Quarterly increase in Opdivo product sales and royalty-related revenueAnnual report
「While competition with rival products intensified, product sales rose by ¥2.1 billion, or 9.5%, year on year to ¥24.4 billion, as use in renal cell carcinoma and gastric cancer remained steady and use in esophageal cancer expanded. Royalty and other revenue rose by ¥0.5 billion, or 2.5%, year on year to ¥21.3 billion.」
In the first quarter, Opdivo product sales increased as use expanded in esophageal cancer and other indications, while royalty and other revenue also increased year on year. - FY2020Full-year decline in product sales and increase in royalty incomeAnnual report
「While use of the antineoplastic drug Opdivo Intravenous Infusion expanded in renal cell carcinoma and other indications, product sales fell by ¥3.3 billion, or 3.6%, from the previous fiscal year to ¥87.3 billion due to the impact of the drug price review in November two years earlier and intensifying competition with rival products. Royalty and other revenue rose by ¥7.1 billion, or 8.9%, to ¥86.8 billion, mainly because royalty income from Bristol Myers Squibb and Merck increased.」
For the full fiscal year, Opdivo product sales declined while royalty and other revenue increased, and the shift in the revenue mix from product sales toward royalty income continued. - FY2020-Q3Third-quarter decline in product sales and increase in royalty incomeAnnual report
「While use of the antineoplastic drug Opdivo Intravenous Infusion expanded in renal cell carcinoma and other indications, product sales fell by ¥3.4 billion, or 4.7%, from the same period of the previous fiscal year to ¥68.0 billion due to the impact of the drug price review in November two years earlier and intensifying competition with rival products. Royalty and other revenue rose by ¥4.8 billion, or 8.1%, to ¥64.2 billion, mainly because royalty income from Bristol Myers Squibb and Merck increased.」
For the nine months ended in the third quarter, Opdivo product sales declined due to the drug price review and intensifying competition, while royalty and other revenue increased, with the shift in the revenue mix continuing. - FY2020-Q2Both product sales and royalty income increased in the first halfAnnual report
「Although the antineoplastic drug Opdivo Intravenous Infusion was affected by the drug price review in November of the previous year and intensifying competition with rival products, product sales rose by ¥1.4 billion, or 3.1%, from the same period of the previous fiscal year to ¥46.8 billion, as use expanded in renal cell carcinoma and other indications and demand was temporarily brought forward ahead of the drug price revision associated with the consumption tax increase. Royalty and other revenue rose by ¥2.9 billion, or 7.3%, to ¥42.2 billion, mainly because royalty income from Bristol Myers Squibb and Merck increased.」
Opdivo product sales rose 3.1% year on year to ¥46.8 billion, while royalty and other revenue rose 7.3% to ¥42.2 billion, with both product sales and royalty-related revenue increasing for the second consecutive quarter. - FY2020-Q1Decline in product sales and increase in royalty incomeAnnual report
「Although use of the antineoplastic drug Opdivo Intravenous Infusion expanded in renal cell carcinoma, product sales fell by ¥0.5 billion, or 2.0%, from the first quarter of the previous fiscal year to ¥22.3 billion due to the impact of the drug price review in November of the previous year and intensifying competition with rival products. Royalty and other revenue rose by ¥3.5 billion, or 20.0%, to ¥20.8 billion, mainly because royalty income from Bristol Myers Squibb for Opdivo Intravenous Infusion and other income increased.」
While Opdivo use expanded, product sales declined due to the drug price review and intensifying competition, whereas royalty and other revenue increased. - FY2019Both product sales and royalty income increased for the full fiscal yearAnnual report
「Although the antineoplastic drug Opdivo Intravenous Infusion was affected by a drug price revision resulting from fundamental reform of the drug pricing system, product sales rose by ¥0.5 billion, or 0.5%, from the previous fiscal year to ¥90.6 billion, as use expanded in renal cell carcinoma and head and neck cancer, for which additional indications were approved two fiscal years ago, and in gastric cancer, for which an additional indication was approved last fiscal year. Royalty and other revenue rose by ¥23.7 billion, or 42.4%, to ¥79.7 billion, mainly because royalty income from Bristol Myers Squibb for Opdivo Intravenous Infusion increased and income was recognized following the transfer of long-listed products, comprising 5 injectable brands and 11 products, to 丸石製薬株式会社.」
For the fiscal year ended March 2019, Opdivo product sales were ¥90.6 billion and royalty and other revenue was ¥79.7 billion, with both revenue streams increasing year on year for the full fiscal year. - FY2019-Q3Both product sales and royalty income increased in the third quarterAnnual report
「Although the antineoplastic drug Opdivo Intravenous Infusion was affected by a drug price revision resulting from fundamental reform of the drug pricing system, product sales rose by ¥2.4 billion, or 3.4%, from the same period of the previous fiscal year to ¥71.3 billion, as use expanded in renal cell carcinoma and head and neck cancer, for which additional indications were approved two fiscal years ago, and in gastric cancer, for which an additional indication was approved last fiscal year. Royalty and other revenue rose by ¥18.8 billion, or 46.2%, to ¥59.4 billion, mainly because royalty income from Bristol Myers Squibb for Opdivo Intravenous Infusion increased and income was recognized following the transfer of long-listed products, comprising 5 injectable brands and 11 products, to 丸石製薬株式会社.」
Opdivo product sales rose 3.4% year on year to ¥71.3 billion on expanded use, while royalty and other revenue rose 46.2% to ¥59.4 billion, with both revenue streams increasing year on year. - FY2019-Q2Both product sales and royalty income increased in the first halfAnnual report
「Although the antineoplastic drug Opdivo Intravenous Infusion was affected by a drug price revision resulting from fundamental reform of the drug pricing system, product sales rose by ¥4.8 billion, or 11.9%, from the same period of the previous fiscal year to ¥45.4 billion, as use expanded in renal cell carcinoma and head and neck cancer, for which additional indications were approved two fiscal years ago, and in gastric cancer, for which an additional indication was approved last fiscal year. Royalty and other operating revenue rose by ¥15.3 billion, or 63.3%, to ¥39.4 billion, mainly because royalty income from Bristol Myers Squibb for Opdivo Intravenous Infusion increased and income was recognized following the transfer of long-listed products, comprising 5 injectable brands and 11 products, to 丸石製薬株式会社.」
Opdivo product sales were ¥45.4 billion and royalty and other operating revenue was ¥39.4 billion, with both product sales and royalty-related revenue increasing year on year for the second consecutive quarter. - FY2019-Q1Both product sales and royalty income increasedAnnual report
「Although the antineoplastic drug Opdivo Intravenous Infusion was affected by a drug price revision resulting from fundamental reform of the drug pricing system, product sales rose by ¥3.0 billion, or 15.0%, from the same period of the previous fiscal year to ¥22.8 billion, as use expanded in renal cell carcinoma and head and neck cancer, for which additional indications were approved two fiscal years ago, and in gastric cancer, for which an additional indication was approved last fiscal year. Royalty and other operating revenue rose by ¥4.9 billion, or 39.6%, to ¥17.4 billion, as royalty income from Bristol Myers Squibb for Opdivo Intravenous Infusion and other income increased.」
Whereas product sales declined in the first quarter of the previous fiscal year due to the drug price reduction, Opdivo product sales increased 15.0% this quarter, and royalty and other operating revenue also increased 39.6%. - FY2018Full-year establishment of the trend of lower product sales and higher royalty incomeAnnual report
「Although use of the antineoplastic drug Opdivo Intravenous Infusion expanded in renal cell carcinoma, head and neck cancer and other cancer types for which additional indications were approved in the previous fiscal year, and in gastric cancer, for which an additional indication was approved in September 2017, product sales fell by ¥13.8 billion, or 13.3%, from the previous fiscal year to ¥90.1 billion, mainly because the drug price was cut by 50% in February 2017. Royalty and other operating revenue rose by ¥25.5 billion, or 83.7%, to ¥55.9 billion, mainly because royalty income from Bristol Myers Squibb for Opdivo Intravenous Infusion increased.」
Despite the expansion in Opdivo use, product sales declined while royalty income increased substantially, confirming a shift in the revenue mix for the full fiscal year. - FY2018-Q3Decline in product sales and increase in royalty incomeAnnual report
「Although use of the antineoplastic drug Opdivo Intravenous Infusion expanded in cancer types for which additional indications were approved in the previous fiscal year, including renal cell carcinoma and head and neck cancer, and in gastric cancer, for which an additional indication was approved in September 2017, product sales fell by ¥13.6 billion, or 16.5%, year on year to ¥69.0 billion, mainly because the drug price was cut by 50% in February 2017. Royalty and other operating revenue rose by ¥18.9 billion, or 86.7%, from the same period of the previous fiscal year to ¥40.6 billion, mainly because royalty income from Bristol Myers Squibb for Opdivo Intravenous Infusion increased.」
While use of Opdivo continued to expand, product sales declined 16.5% year on year due to the drug price reduction, while royalty and other operating revenue increased 86.7%. - FY2018-Q2Decline in product sales and increase in royalty incomeAnnual report
「Although use of the antineoplastic drug Opdivo Intravenous Infusion expanded in cancer types for which additional indications were approved last fiscal year, including renal cell carcinoma and head and neck cancer, product sales fell by ¥12.7 billion, or 23.8%, from the same period of the previous fiscal year to ¥40.6 billion, mainly because the drug price was cut by 50% in February 2017. Royalty and other operating revenue rose by ¥13.7 billion, or 131.2%, to ¥24.1 billion, mainly because royalty income from Bristol Myers Squibb for Opdivo Intravenous Infusion increased.」
While use of Opdivo continued to expand, product sales declined 23.8% year on year due to the drug price reduction, while royalty and other operating revenue increased 131.2%. The shift in the revenue mix has become more pronounced. - FY2018-Q1Changes in Revenue CompositionAnnual report
「Although use of the antineoplastic drug Opdivo Intravenous Infusion expanded in cancer types for which additional indications were approved last fiscal year, including renal cell carcinoma and head and neck cancer, product sales fell by ¥5.4 billion, or 21.4%, from the same period of the previous fiscal year to ¥19.8 billion, mainly because the drug price was cut by 50% in February 2017. Meanwhile, royalty income from Bristol Myers Squibb for Opdivo Intravenous Infusion rose by ¥4.6 billion, or 108.4%, to ¥8.9 billion.」
While use of Opdivo continued to expand, product sales declined following the drug price reduction, whereas royalty income increased. The revenue mix shifted from product sales toward royalty income. - FY2017AdvancedAnnual report
「Opdivo I.V. Injection, an antineoplastic agent, rose by ¥82.8 billion, or 391.3%, from the previous fiscal year to ¥103.9 billion, driven in part by expanded use for unresectable advanced or recurrent non-small cell lung cancer. Royalty income from Bristol Myers Squibb for Opdivo I.V. Injection rose by ¥18.5 billion, or 224.4%, from the previous fiscal year to ¥26.7 billion.」
Opdivo product sales were ¥103.9 billion and royalty income was ¥26.7 billion, confirming growth in both product sales and royalty income for the full fiscal year. - FY2017-Q3AdvancedAnnual report
「Opdivo I.V. Injection sales rose by ¥76.9 billion, or 1,360.4%, from the same period of the previous fiscal year to ¥82.6 billion, driven by expanded use for unresectable advanced or recurrent non-small cell lung cancer. Royalty income from Bristol Myers Squibb for Opdivo I.V. Injection rose by ¥14.1 billion, or 295.7%, from the same period of the previous fiscal year to ¥18.9 billion.」
Opdivo product sales totaled ¥82.6 billion and royalty income totaled ¥18.9 billion, representing substantial year-on-year increases. - FY2017-Q2AdvancedAnnual report
「Opdivo I.V. Injection, an antineoplastic agent launched in September 2014 as the world's first anti-PD-1 monoclonal antibody, rose by ¥50.3 billion from the same period of the previous fiscal year, or 1,714.0%, to ¥53.3 billion following the addition in December 2015 of an indication for unresectable advanced or recurrent non-small cell lung cancer. Royalty income from Bristol Myers Squibb for Opdivo I.V. Injection rose by ¥6.5 billion, or 296.7%, from the same period of the previous fiscal year to ¥8.7 billion.」
Opdivo product sales totaled ¥53.3 billion and royalty income totaled ¥8.7 billion, increases of ¥50.3 billion and ¥6.5 billion, respectively, from the same period of the previous fiscal year. - FY2017-Q1AdvancedAnnual report
「Opdivo I.V. Injection, an antineoplastic agent launched in September 2014 as the world's first anti-PD-1 monoclonal antibody, rose by ¥23.8 billion from the same period of the previous fiscal year, or 1,640.7%, to ¥25.2 billion following the addition in December 2015 of an indication for unresectable advanced or recurrent non-small cell lung cancer. Royalty income from Bristol Myers Squibb for Opdivo I.V. Injection also increased.」
Opdivo sales totaled ¥25.2 billion, an increase of ¥23.8 billion, or 1,640.7%, year on year, while royalty income also increased. - FY2016First statedAnnual report
「Opdivo I.V. Injection sales rose by ¥18.6 billion, or 741.0%, from the previous fiscal year to ¥21.2 billion, following the addition in December 2015 of an indication for unresectable advanced or recurrent non-small cell lung cancer. Royalty income from Bristol Myers Squibb for Opdivo also increased substantially.」
The company emphasizes that Opdivo drove sales growth for the fiscal year, supported by the addition of indications and growth in royalty income.